| INTRODUCTION
Persistent infection with high-risk (HR) HPV genotypes leads to the development of cervical cancer. [1] [2] [3] While the Papanicolaou (Pap) smear cytology test has some limitations, including inter-operator variability and low sensitivity, HR HPV testing has improved patient management by providing a more accurate risk assessment for cervical cancer or its precursors.
4,5
The AdvanSure HPV GenoBlot assay (AdvanSure assay; LG Life Sciences, Seoul, Korea) is a recently developed HPV detection assay based on real-time polymerase chain reaction (PCR) and reverse hybridization.
The primary objective of this study was to compare the performance of the AdvanSure and Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, MD, USA) assays for the screening of HR HPV infection.
We also analyzed discordant results and specimens that were positive on both assays using restriction fragment mass polymorphism (RFMP) genotyping analysis based on matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry analysis to evaluate genotype detection.
| MATERIALS AND METHODS

| Subjects and sample collection
We conducted this study in a routine diagnostic laboratory setting and used 795 cervical swab specimens obtained from Korean patients seeking routine health check-ups between September and October 2014. The medical records of each participant were reviewed using an electronic medical records system to collect information regarding age and cytology results. The specimens were obtained using a DNA PAP Cervical Sampler and specimen transport medium (Qiagen). Each specimen was divided into two aliquots and then promptly submitted for HPV detection using HC2 and AdvanSure assay. DNA was extracted from the AdvanSure assay aliquot using the Smart Lab 
| AdvanSure HPV GenoBlot assay
The AdvanSure assay uses single-tube nested multiplex asymmet- 
| RFMP genotyping assay
The details of the RFMP assay protocol were described previously. 6, 7 Briefly, 4 μL of DNA was amplified with PGMY09/11 primers, which consist of two non-degenerate pools of L1 consensus primers. The second round primer pairs consisted of an RFMP sense primer specific to bases 6584-6603 (5′-GCMCAGGGHCAYAAGGATGAATG G-3′) and an RFMP antisense primer specific to bases 6657-6626 
| RESULTS
This study included 855 cervical swab specimens from patients whose Table 1 . Among the seven cases that were found to be positive on HC2 and negative on AdvanSure, all were found to be positive for a single HPV genotype, five were positive for non-16/18 HR HPV and two showed no amplification. All five of the specimens that were negative on HC2 and positive on AdvanSure were identified as having a single HPV genotype, four were positive for LR HPV and one showed no amplification.
| DISCUSSION
The AdvanSure assay and HC2 assays showed good agreement of Discordant results may be caused by differences in the analytical sensitivity of the assays. In some studies, significant differences in viral load were observed according to cervical intraepithelial neoplasia (CIN) grade and HPV DNA sample volume or cellularity.
8-10 Since we performed a prospective, non-selective study with clinical specimens from health check-up examinations, the cytology findings of nearly all enrolled cases were normal (90.7%), implying that the enrolled participants might have a lower HPV DNA viral load. Thus, some aliquots of the original specimens might have had an insufficient volume of cells needed to acquire accurate results.
The present study was limited to clinical specimens, most of which were cytologically normal, for the detection of HR HPV infection.
Further evaluation of the clinical performance of the AdvanSure assay in cytologically abnormal CIN2+ specimens is needed.
In conclusion, we evaluated the recently developed AdvanSure 
